LPL Financial’s Soleno Therapeutics SLNO Stock Holding History

LPL Financial’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,720	Closed	-$357K	–	6141
2025 Q4	$357K	Buy	+7,720	New	+$423K	﹤0.01%	5012

Other funds holding SLNO

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

LPL Financial's SLNO Position: Q1 2026 in Review

LPL Financial sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 7,720 shares — an estimated $357K sold.

LPL Financial first reported a position in SLNO in Q4 2025 and held it in 1 quarter. The position peaked at $357K in Q4 2025. 227 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

LPL Financial reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
LPL Financial sold 7,720 Soleno Therapeutics shares in Q1 2026, an estimated $357K.
LPL Financial first reported a position in Soleno Therapeutics in Q4 2025 and held it in 1 quarter.
LPL Financial's Soleno Therapeutics position peaked at $357K in Q4 2025.
227 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.